

SUPPLEMENTAL TABLE 1

Immediate risk of CIN3+ by age, CDC's NBCCEDP

Population	Test results		Age category	N	CIN3+	Immediate CIN3+ risk	SE	95% LCL	95% UCL
	HPV	Cytology							
Screened in the past 5 y	Positive	NILM	30–44	4475	56	2.68	0.33	2.03	3.33
			45–64	6840	59	2.12	0.26	1.60	2.64
		ASC-US	30–44	5107	257	5.10	0.28	4.54	5.65
			45–64	6647	288	4.06	0.22	3.62	4.50
		LSIL	30–44	1822	90	4.59	0.41	3.78	5.39
			45–64	1906	69	3.65	0.34	2.98	4.31
		ASC-H	30–44	257	69	27.63	2.13	23.44	31.81
			45–64	310	69	23.11	1.88	19.43	26.80
		AGC	30–44	109	33	32.23	3.32	25.72	38.73
			45–64	135	36	27.24	2.99	21.38	33.10
	HSIL+	30–44	403	184	52.36	2.08	48.29	56.43	
		45–64	344	153	46.40	2.12	42.24	50.56	
	Negative	NILM	30–44	53,342	10				
			45–64	99,264	9				
		ASC-US	30–44	8216	11				
			45–64	16,970	34				
		LSIL	30–44	572	5	0.89	0.35	0.20	1.59
			45–64	889	6	1.03	0.39	0.27	1.79
		ASC-H	30–44	110	7	4.50	1.41	1.73	7.26
			45–64	183	7	5.16	1.46	2.30	8.02
AGC		30–44	196	1	2.67	0.79	1.13	4.21	
		45–64	473	18	3.07	0.74	1.62	4.53	
HSIL+	30–44	35	12	30.16	6.11	18.18	42.15		
	45–64	51	12	33.30	5.94	21.65	44.94		
Never or rarely screened	Positive	NILM	30–44	2442	30	3.34	0.52	2.33	4.36
			45–64	4112	38	3.69	0.56	2.60	4.78
		ASC-US	30–44	2091	125	6.27	0.47	5.35	7.19
			45–64	3039	190	6.91	0.44	6.04	7.78
		LSIL	30–44	843	42	4.91	0.58	3.76	6.05
			45–64	1019	45	5.41	0.62	4.19	6.63
		ASC-H	30–44	108	28	32.33	3.14	26.18	38.49
			45–64	185	60	34.64	3.10	28.56	40.72
		AGC	30–44	60	18	43.58	4.28	35.19	51.97
			45–64	115	49	46.14	4.16	37.98	54.30
		HSIL+	30–44	307	175	64.13	2.20	59.82	68.45
			45–64	360	227	66.48	2.08	62.40	70.56

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 1

Immediate risk of CIN3+ by age, CDC's NBCCEDP (continued)

Population	Test results		Age category	N	CIN3+	Immediate CIN3+ risk	SE	95% LCL	95% UCL	
	HPV	Cytology								
	Negative	NILM	30–44	27,401	3					
			45–64	59,786	10					
		ASC-US	30–44	3099	2					
			45–64	6827	8					
		LSIL	30–44	280	2	0.58	0.36	0.00	1.27	
			45–64	421	1	1.02	0.59	0.00	2.17	
	ASC-H	30–44	32	1	3.18	1.46	0.31	6.04		
		45–64	128	6	5.50	2.03	1.53	9.47		
	AGC	30–44	78	2	4.91	1.56	1.84	7.97		
		45–64	308	23	8.39	1.64	5.18	11.59		
	HSIL+	3–44	29	11	40.84	7.39	26.36	55.32		
		45–64	56	28	55.05	6.32	42.67	67.43		
	Unknown screening history	Positive	NILM	30–44	1128	13	3.29	0.74	1.85	4.74
				45–64	1437	8	3.36	0.74	1.90	4.82
			ASC-US	30–44	1087	69	6.45	0.68	5.11	7.79
				45–64	1003	57	6.58	0.72	5.16	7.99
			LSIL	30–44	433	29	8.34	1.18	6.02	10.66
				45–64	405	30	8.50	1.20	6.14	10.86
ASC-H		30–44	75	14	21.93	4.31	13.48	30.38		
		45–64	48	9	22.29	4.41	13.63	30.94		
AGC		30–44	39	11	33.11	5.93	21.50	44.73		
		45–64	37	11	33.57	6.00	21.81	45.34		
HSIL+		30–44	128	64	60.19	3.59	53.16	67.23		
		45–64	123	72	60.69	3.57	53.69	67.69		
Negative		NILM	30–44	12,054	0					
				45–64	20,015	2				
			ASC-US	30–44	1228	3				
				45–64	2042	2				
			LSIL	30–44	127	0	1.61	1.07	0.00	3.69
				45–64	166	3	2.28	1.37	0.00	4.97
	ASC-H	30–44	13	0	2.23	2.42	0.00	6.97		
		45–64	30	1	3.16	3.12	0.00	9.28		
	AGC	30–44	34	0	3.96	2.36	0.00	8.57		
		45–64	83	5	5.56	2.49	0.67	10.45		
	HSIL+	30–44	12	7	36.48	11.90	13.15	59.81		
		45–64	15	4	45.08	12.03	21.51	68.65		

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 1

Immediate risk of CIN3+ by age, CDC's NBCCEDP (continued)

Population	Test results		Age category	N	CIN3+	Immediate CIN3+ risk	SE	95% LCL	95% UCL
	HPV	Cytology							
Never or rarely screened and unknown screening	Positive	NILM	30–44	3570	43	3.35	0.42	2.52	4.18
			45–64	5549	46	3.65	0.45	2.77	4.54
		ASC-US	30–44	3178	194	6.30	0.38	5.55	7.05
			45–64	4042	247	6.85	0.38	6.11	7.59
		LSIL	30–44	1276	71	5.88	0.54	4.83	6.94
			45–64	1424	75	6.40	0.57	5.29	7.51
		ASC-H	30–44	183	42	29.47	2.56	24.46	34.49
			45–64	233	69	31.37	2.58	26.32	36.43
		AGC	30–44	99	29	40.29	3.48	33.46	47.11
			45–64	152	60	42.46	3.45	35.70	49.23
	HSIL+	30–44	435	239	62.97	1.88	59.30	66.65	
		45–64	483	299	65.04	1.80	61.51	68.56	
	Negative	NILM	30–44	39,455	3				
			45–64	79,801	12				
		ASC-US	30–44	4327	5				
			45–64	8869	10				
		LSIL	30–4	407	2	4.67	1.30	2.12	7.23
			45–64	587	4	39.58	6.26	27.30	51.85
		ASC-H	30–44	45	1	0.01	0.00	0.00	0.01
			45–64	158	7	0.08	0.03	0.03	0.13
AGC		30–44	112	2	1.42	0.59	0.27	2.57	
		45–64	391	28	5.05	1.74	1.63	8.47	
HSIL+	30–44	41	18	7.77	1.39	5.04	10.50		
	45–64	71	32	52.95	5.61	41.96	63.94		

AGC, atypical glandular cell; ASC-H, atypical squamous cells-cannot exclude; ASC-US, atypical squamous cells of uncertain significance; CDC, Centers for Disease Control and Prevention; CIN3, cervical intraepithelial neoplasia grade III or greater; HSIL, high-grade squamous intraepithelial lesion; HSIL HPV, human papillomavirus; KPNC, Kaiser Permanente Northern California; LCL, lower confidence limits; LSIL, low-grade squamous intraepithelial lesion; NBCCEDP, National Breast and Cervical Cancer Early Detection Program; NILM, negative for intraepithelial lesion or malignancy; SE, standard error; UCL, upper confidence limits.

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. *Am J Obstet Gynecol* 2020.

SUPPLEMENTAL TABLE 2
Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
Screened within 5 y	White	Positive	NILM	4087	5.77	37	2.46	1.49	3.44
			ASC-US	5120	7.22	232	4.36	3.76	4.97
			LSIL	1534	2.16	72	4.69	3.54	5.84
			ASC-H	232	0.33	51	23.37	17.7	29.04
			HSIL+	332	0.47	151	49.5	43.83	55.17
			AGC	129	0.18	34	26.89	18.93	34.86
		Negative	NILM	47,541	67.07	6			
			ASC-US	10,768	15.19	21			
			LSIL	615	0.87	7	1.51	0.09	2.93
	Black	Positive	NILM	1494	5.77	9	2.5	0.89	4.11
			ASC-US	1354	5.23	61	4.66	3.42	5.91
			LSIL	354	1.37	19	5.94	3.28	8.6
			ASC-H	59	0.23	16	28.85	16.53	41.16
			HSIL+	82	0.32	37	52.11	40.49	63.73
			AGC	23	0.09	3	16.67	0	33.89
		Negative	NILM	18,590	71.76	1			
			ASC-US	3610	13.94	5			
			LSIL	187	0.72	1	0.89	0	2.64
Asian or Pacific Islander	Positive	NILM	470	4.91	7	1.49	0.6	3.04	
		ASC-US	479	5	26	5.43	3.58	7.85	
		LSIL	136	1.42	7	5.15	2.09	10.32	
		ASC-H	21	0.22	5	23.81	8.22	47.17	

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 2

Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
			HSIL+	24	0.25	12	50	29.12	70.88
			AGC	13	0.14	4	30.77	9.09	61.43
		Negative	NILM	7499	78.26	2			
			ASC-US	872	9.1	3			
			LSIL	39	0.41	2	5.13	0.63	17.32
			ASC-H	8	0.08	0			
			HSIL+	1	0.01	0			
			AGC	20	0.21	0			
	Hispanic	Positive	Normal	4290	4.84	52	2.4	1.5	3.3
			ASC-US	4035	4.55	195	4.57	3.89	5.25
			LSIL	1428	1.61	55	3.43	2.41	4.44
			ASC-H	220	0.25	56	24.88	18.96	30.8
			HSIL+	256	0.29	113	47.6	41.13	54.07
			AGC	71	0.08	25	36.92	25.19	48.66
		Negative	NILM	68,735	77.49	8			
			ASC-US	8787	9.91	16			
			LSIL	567	0.64	1	0.29	0	0.87
			ASC-H	96	0.11	5	5.62	0.84	10.4
			HSIL+	24	0.03	6	30	10.06	49.95
			AGC	188	0.21	5	2.98	0.4	5.55
	American Indian/Alaskan Native	Positive	NILM	723	7.33	9	1.38	0.01	2.75
			ASC-US	564	5.72	22	4.37	2.5	6.25
			LSIL	210	2.13	3	1.02	0	2.58
			ASC-H	26	0.26	10	45.46	24.65	66.26
			HSIL+	41	0.42	19	57.58	40.71	74.44
			AGC	6	0.06	3	50	10	90.01
		Negative	NILM	7475	75.76	2			
			ASC-US	766	7.76	0			

SUPPLEMENTAL TABLE 2

Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
			LSIL	33	0.33	0			
			ASC-H	7	0.07	0			
			HSIL+	3	0.03	1	33.33	0.84	90.57
			AGC	13	0.13	0			
	Multiracial	Positive	NILM	126	8.2	0			
			ASC-US	79	5.14	3	4.41	0.92	12.36
			LSIL	31	2.02	1			
			ASC-H	4	0.26	0			
			HSIL+	5	0.33	1	20	0.51	71.64
			AGC	0	0	0			
		Negative	NILM	1144	74.48	0			
			ASC-US	131	8.53	0			
			LSIL	12	0.78	0			
			ASC-H	1	0.07	0			
			HSIL+	0	0	0			
			AGC	3	0.2	0			
	Unknown	Positive	NILM	125	5.71	1	0.8	0.02	4.38
			ASC-US	123	5.61	6	4.88	1.81	10.32
			LSIL	35	1.6	2	5.71	0.7	19.16
			ASC-H	5	0.23	0			
			HSIL+	7	0.32	4	57.14	18.41	90.1
			AGC	2	0.09	0			
		Negative	NILM	1622	74.03	0			
			ASC-US	252	11.5	0			
			LSIL	8	0.37	0			
			ASC-H	2	0.09	0			
			HSIL+	4	0.18	1	25	0.63	80.59
			AGC	6	0.27	0			

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 2
Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
Rarely or never screened	White	Positive	NILM	2504	6	34	5.18	3.27	7.09
			ASC-US	2368	5.67	163	7.48	6.32	8.64
			LSIL	847	2.03	50	6.33	4.5	8.16
			ASC-H	130	0.31	40	33.39	24.66	42.12
			HSIL+	334	0.8	205	66.23	60.92	71.53
			AGC	106	0.25	47	50.54	40.38	60.7
			Negative	NILM	30,308	72.62	8		
	ASC-US	4563	10.93	7					
	LSIL	274	0.66	1	0.71	0	2.11		
	ASC-H	74	0.18	2	3.33	0	7.87		
	HSIL+	39	0.09	19	51.43	34.87	67.99		
	AGC	189	0.45	12	7.69	3.51	11.88		
	Black	Positive	NILM	921	6.23	3	1.28	0	3.05
			ASC-US	637	4.31	44	7.73	5.4	10.07
LSIL			189	1.28	7	4.48	0.96	8.01	
ASC-H			34	0.23	12	44.44	25.7	63.19	
HSIL+			67	0.45	42	68.85	57.23	80.47	
AGC			16	0.11	4	30.77	5.68	55.86	
Negative			NILM	11,227	75.89	1			
ASC-US		1497	10.12	1					
LSIL		96	0.65	0					
ASC-H		32	0.22	1	4	0	11.64		
HSIL+		14	0.09	6	46.15	19.19	73.12		
AGC		64	0.43	5	9.09	1.62	16.56		
Asian or Pacific Islander		Positive	NILM	397	4.78	6	3.93	0	8.41
			ASC-US	285	3.43	19	6.98	3.76	10.2
	LSIL		107	1.29	2	2.22	0	5.27	
	ASC-H		25	0.3	7	28.57	9.25	47.89	

SUPPLEMENTAL TABLE 2

Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
			HSIL+	41	0.49	25	69.44	54.4	84.49
			AGC	9	0.11	1	16.67	0	46.49
		Negative	NILM	6879	82.82	0			
			ASC-US	498	6	1			
			LSIL	39	0.47	0			
			ASC-H	5	0.06	2	40	5.27	85.34
			HSIL+	6	0.07	4	66.67	22.28	95.67
			AGC	15	0.18	1	6.67	0.17	31.95
	Hispanic	Positive	NILM	2197	5.47	21	2.53	0.95	4.11
			ASC-US	1482	3.69	79	5.56	4.31	6.82
			LSIL	566	1.41	21	4.3	2.5	6.1
			ASC-H	79	0.2	22	31.89	20.89	42.88
			HSIL+	183	0.46	112	65.5	58.37	72.62
			AGC	34	0.08	11	37.93	20.27	55.59
		Negative	NILM	32,369	80.64	2			
			ASC-US	2809	7	0			
			LSIL	245	0.61	2	0.82	0.1	2.92
			ASC-H	44	0.11	2	4.55	0.56	15.47
			HSIL+	24	0.06	9	37.5	18.8	59.41
			AGC	110	0.27	6	5.45	2.03	11.49
	American Indian/Alaskan Native	Positive	NILM	443	7.27	3	0.96	0.02	5.24
			ASC-US	286	4.69	8	3.17	1.28	6.42
			LSIL	107	1.76	3	2.6	0.32	9.07
			ASC-H	20	0.33	6	35.29	14.21	61.67
			HSIL+	30	0.49	10	34.62	17.21	55.67
			AGC	6	0.1	1	25	0.63	80.59
		Negative	NILM	4786	78.55	1			
			ASC-US	374	6.14	0			

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 2
Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
			LSIL	29	0.48	0			
			ASC-H	4	0.07	0			
			HSIL+	2	0.03	1	50	1.26	98.74
			AGC	6	0.1	1	20	0.51	71.64
	Multiracial	Positive	NILM	33	4.55	1			
			ASC-US	22	3.03	0			
			LSIL	16	2.21	0			
			ASC-H	3	0.41	1	50	1.26	98.74
			HSIL+	4	0.55	3	75	19.41	99.37
			AGC	3	0.41	2	100	15.81	100
		Negative	NILM	580	80	1			
			ASC-US	56	7.72	1			
			LSIL	7	0.97	0			
			ASC-H	1	0.14	0			
			HSIL+	0	0	0			
			AGC	0	0	0			
	Unknown	Positive	NILM	59	4.44	0			
			ASC-US	50	3.76	2	4	0.49	13.71
			LSIL	30	2.26	4	13.33	3.76	30.72
			ASC-H	2	0.15	0			
			HSIL+	8	0.6	5	62.5	24.49	91.48
			AGC	1	0.08	1	100	2.5	100
		Negative	NILM	1038	78.05	0			
			ASC-US	129	9.7	0			
			LSIL	11	0.83	0			
			ASC-H	0	0	0			
			HSIL+	0	0	0			
			AGC	2	0.15	0			

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 2

Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
Unknown	White	Positive	NILM	890	6.65	6	2.83	0.6	5.06
			ASC-US	907	6.78	61	7.38	5.54	9.23
			LSIL	328	2.45	26	10.08	6.33	13.83
			ASC-H	60	0.45	9	15.81	5.24	26.39
			HSIL+	114	0.85	67	62.62	53.45	71.78
			AGC	41	0.31	7	19.44	6.52	32.37
			Negative	NILM	9565	71.52	0		
	ASC-US	1268	9.48	1					
	LSIL	114	0.85	2	3.03	0	7.23		
	ASC-H	15	0.11	0					
	HSIL+	10	0.07	4	50	14.81	85.19		
	AGC	62	0.46	4	7.55	0.68	14.41		
	Black	Positive	NILM	476	7.02	1	0.21	0.01	1.16
			ASC-US	331	4.88	19	5.74	3.49	8.82
LSIL			104	1.53	7	6.73	2.75	13.38	
ASC-H			21	0.31	3	14.29	3.05	36.34	
HSIL+			42	0.62	24	57.14	40.96	72.28	
AGC			11	0.16	5	45.45	16.75	76.62	
Negative			NILM	5090	75.03	0			
ASC-US		632	9.32	0					
LSIL		49	0.72	0					
ASC-H		7	0.1	1	14.29	0.36	57.87		
HSIL+		4	0.06	2	50	6.76	93.24		
AGC		17	0.25	0					
Asian or Pacific Islander		Positive	NILM	170	5.86	3	1.76	0.37	5.07
			ASC-US	86	2.97	6	6.98	2.6	14.57
	LSIL		47	1.62	3	6.38	1.34	17.54	
	ASC-H		3	0.1	0				

SUPPLEMENTAL TABLE 2

Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
			HSIL+	14	0.48	10	71.43	41.9	91.61
			AGC	5	0.17	3	60	14.66	94.73
		Negative	NILM	2457	84.72	0			
			ASC-US	100	3.45	0			
			LSIL	10	0.34	0			
			ASC-H	2	0.07	0			
			HSIL+	0	0	0			
			AGC	6	0.21	1	16.67	0.42	64.12
	Hispanic	Positive	NILM	923	5.36	8	0.87	0.37	1.7
			ASC-US	690	4	38	5.51	3.93	7.48
			LSIL	338	1.96	23	6.8	4.36	10.04
			ASC-H	36	0.21	10	27.78	14.2	45.19
			HSIL+	76	0.44	33	43.42	32.08	55.29
			AGC	17	0.1	6	35.29	14.21	61.67
		Negative	NILM	13,850	80.37	2			
			ASC-US	1130	6.56	4			
			LSIL	115	0.67	1	0.87	0.02	4.75
			ASC-H	16	0.09	0			
			HSIL+	11	0.06	4	36.36	10.93	69.21
			AGC	31	0.18	0			
	American Indian/Alaskan Native	Positive	NILM	38	8.05	1	20	0.51	71.64
			ASC-US	32	6.78	0			
			LSIL	8	1.69	0			
			ASC-H	2	0.42	0			
			HSIL+	3	0.64	1	50	1.26	98.74
			AGC	1	0.21	1	100	2.5	100
		Negative	NILM	330	69.92	0			
			ASC-US	53	11.23	0			

SUPPLEMENTAL TABLE 2

Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
			LSIL	4	0.85	0			
			ASC-H	1	0.21	0			
			HSIL+	0	0	0			
			AGC	0	0	0			
	Multiracial	Positive	NILM	7	4.79	0			
			ASC-US	12	8.22	1			
			LSIL	2	1.37	0			
			ASC-H	0	0	0			
			HSIL+	0	0	0			
			AGC	0	0	0			
		Negative	NILM	106	72.6	0			
			ASC-US	18	12.33	0			
			LSIL	0	0	0			
			ASC-H	1	0.68	0			
			HSIL+	0	0	0			
			AGC	0	0	0			
	Unknown	Positive	NILM	61	7.15	2	3.28	0.4	11.35
			ASC-US	32	3.75	1	3.12	0.08	16.22
			LSIL	11	1.29	0			
			ASC-H	1	0.12	1	100	2.5	100
			HSIL+	2	0.23	1	50	1.26	98.74
			AGC	1	0.12	0			
		Negative	NILM	671	78.66	0			
			ASC-US	69	8.09	0			
			LSIL	1	0.12	0			
			ASC-H	1	0.12	0			
			HSIL+	2	0.23	1	50	1.26	98.74
			AGC	1	0.12	0			

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 2

Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
Unknown and rarely or never screened	White	Positive	NILM	3394	25.38	40	4.55	3.02	6.07
			ASC-US	3275	24.49	224	7.46	6.48	8.44
			LSIL	1175	8.79	76	7.34	5.66	9.01
			ASC-H	190	1.42	49	28.27	21.27	35.26
			HSIL+	448	3.35	272	65.29	60.7	69.89
			AGC	147	1.1	54	41.86	33.35	50.38
			Negative	NILM	39,873	298.14	8		
	ASC-US	5831	43.6	8					
	LSIL	388	2.9	3	1.46	0	3.09		
	ASC-H	89	0.67	2	2.74	0	6.48		
	HSIL+	49	0.37	23	50.74	35.68	65.8		
	AGC	251	1.88	16	7.66	4.05	11.26		
	Black	Positive	NILM	1397	20.59	4	1.17	0	2.48
			ASC-US	968	14.27	63	7.2	5.36	9.04
LSIL			293	4.32	14	6.31	3.11	9.5	
ASC-H			55	0.81	15	34.09	20.08	48.1	
HSIL+			109	1.61	66	66.67	57.38	75.95	
AGC			27	0.4	9	40.91	20.37	61.46	
Negative			NILM	16,317	240.52	1			
ASC-US		2129	31.38	1					
LSIL		145	2.14	0					
ASC-H		39	0.57	2	5.13	0.63	17.32		
HSIL+		18	0.27	8	44.44	21.53	69.24		
AGC		81	1.19	5	6.17	2.03	13.82		
Asian or Pacific Islander		Positive	NILM	567	19.55	9	3.84	0	7.92
			ASC-US	371	12.79	25	6.69	3.91	9.47
	LSIL		154	5.31	5	3.79	0.53	7.05	
	ASC-H		28	0.97	7	25	7.68	42.32	

SUPPLEMENTAL TABLE 2

Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
			HSIL+	55	1.9	35	71.43	58.78	84.08
			AGC	14	0.48	4	40.01	9.65	70.38
		Negative	NILM	9336	321.93	0			
			ASC-US	598	20.62	1			
			LSIL	49	1.69	0			
			ASC-H	7	0.24	2	28.57	3.67	70.96
			HSIL+	6	0.21	4	66.67	22.28	95.67
			AGC	21	0.72	2	9.52	1.17	30.38
	Hispanic	Positive	NILM	3120	18.1	29	2.97	1.7	4.25
			ASC-US	2172	12.6	117	5.72	4.67	6.78
			LSIL	904	5.25	44	5.38	3.77	7
			ASC-H	115	0.67	32	33.33	23.9	42.76
			HSIL+	259	1.5	145	61.97	55.75	68.19
			AGC	51	0.3	17	38.64	24.25	53.02
		Negative	NILM	46,219	268.2	4			
			ASC-US	3939	22.86	4			
			LSIL	360	2.09	3	1.61	0	3.42
			ASC-H	60	0.35	2	3.85	0	9.07
			HSIL+	35	0.2	13	37.5	20.73	54.27
			AGC	141	0.82	6	4.92	1.08	8.76
	American Indian/Alaskan Native	Positive	NILM	481	7.33	4	1.83	0.22	6.47
			ASC-US	318	4.84	8	2.85	1.15	5.77
			LSIL	115	1.75	3	2.41	0.29	8.43
			ASC-H	22	0.34	6	31.58	12.58	56.55
			HSIL+	33	0.5	11	35.71	18.64	55.93
			AGC	7	0.11	2	40	5.27	85.34
		Negative	NILM	5116	77.93	1			
			ASC-US	427	6.5	0			

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 2
Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
			LSIL	33	0.5	0			
			ASC-H	5	0.08	0			
			HSIL+	2	0.03	1	50	1.26	98.74
			AGC	6	0.09	1	20	0.51	71.64
	Multiracial	Positive	NILM	40	4.59	1			
			ASC-US	34	3.9	1			
			LSIL	18	2.07	0			
			ASC-H	3	0.34	1	50	1.26	98.74
			HSIL+	4	0.46	3	75	19.41	99.37
			AGC	3	0.34	2	67	15.81	100
		Negative	NILM	686	78.76	1			
			ASC-US	74	8.5	1			
			LSIL	7	0.8	0			
			ASC-H	2	0.23	0			
			HSIL+	0	0	0			
			AGC	0	0	0			
	Unknown	Positive	NILM	120	14.07	2	1.67	0.2	5.89
			ASC-US	82	9.61	3	3.66	0.76	10.32
			LSIL	41	4.81	4	9.76	2.72	23.13
			ASC-H	3	0.35	1	33.33	0.84	90.57
			HSIL+	10	1.17	6	60	26.24	87.84
			AGC	2	0.23	1	50	1.26	98.74
		Negative	NILM	1709	200.35	0			
			ASC-US	198	23.21	0			

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. *Am J Obstet Gynecol* 2020.

(continued)

SUPPLEMENTAL TABLE 2

Immediate risk of CIN3+ by race and ethnicity, CDC's NBCCEDP (continued)

Population	Race	Test result		Frequency	%	Case	Prevalent risk	95% LCL	95% UCL
		HPV	Papanicolaou						
			LSIL	12	1.41	0			
			ASC-H	1	0.12	0			
			HSIL+	2	0.23	1	50	1.26	98.74
			AGC	3	0.35	0			

AGC, atypical glandular cell; ASC-H, atypical squamous cells-cannot exclude; ASC-US, atypical squamous cells of uncertain significance; CDC, Centers for Disease Control and Prevention; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; NBCCEDP, National Breast and Cervical Cancer Early Detection Program; NILM, negative for intraepithelial lesion or malignancy; UCL, upper confidence limits.

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. *Am J Obstet Gynecol* 2020.

SUPPLEMENTAL TABLE 3

Immediate CIN2+ risk after the first screening with HPV by age, CDC's NBCCEDP

Population	Test results		Age category	N	CIN2+	Immediate CIN2+ risk	SE	95% LCL	95% UCL
	HPV	Cytology							
Screened in the past 5 y	Positive	NILM	30–44	4475	105	5.42	0.48	4.49	6.36
			45–64	6840	91	3.43	0.31	2.82	4.03
			ALL	11,315	196	4.25	0.37	3.53	4.96
		ASC-US	30–44	5107	637	12.61	0.44	11.74	13.48
			45–64	6647	578	8.19	0.32	7.57	8.81
			ALL	11,754	1215	10.12	0.30	9.53	10.70
		LSIL	30–44	1822	249	13.78	0.71	12.40	15.17
			45–64	1906	161	9.00	0.52	7.99	10.01
			ALL	3728	410	11.37	0.56	10.26	12.47
	ASC-H	30–44	257	105	41.98	2.32	37.43	46.54	
		45–64	310	95	30.92	2.03	26.94	34.89	
		ALL	567	200	35.90	2.10	31.78	40.01	
	AGC	30–44	109	44	45.39	3.51	38.52	52.26	
		45–64	135	48	33.96	3.16	27.77	40.14	
		ALL	244	92	38.92	3.28	32.49	45.34	
	HSIL+	30–44	403	266	75.67	1.65	72.43	78.90	
		45–64	344	220	65.79	2.01	61.85	69.74	
		ALL	747	486	71.12	1.76	67.68	74.57	
	Negative	NILM	30–44	53,342	22				
			45–64	99,264	22				
			ALL	152,606	44				
		ASC-US	30–44	8216	41				
			45–64	16,970	63				
			ALL	25,186	104				
LSIL		30–44	572	14	3.31	0.74	1.86	4.77	
		45–64	889	17	2.56	0.57	1.44	3.67	
		ALL	1461	31	2.85	0.59	1.70	4.01	
ASC-H		30–44	110	15	11.73	2.35	7.14	16.33	
		45–64	183	14	9.24	1.82	5.67	12.80	
		ALL	293	29	10.19	1.86	6.55	13.83	
AGC		30–44	196	7	6.04	1.23	3.62	8.46	
		45–64	473	26	4.69	0.87	2.99	6.40	
		ALL	669	33	5.09	0.89	3.34	6.84	
HSIL+	30–44	35	15	46.50	6.35	34.06	58.94		
	45–64	51	18	39.96	5.89	28.42	51.50		
	ALL	86	33	42.67	5.71	31.47	53.86		
Never/rarely screened	Positive	NILM	30–44	2442	52	6.15	0.76	4.66	7.64
			45–64	4112	60	4.98	0.62	3.76	6.21

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 3

Immediate CIN2+ risk after the first screening with HPV by age, CDC's NBCCEDP (continued)

Population	Test results		Age category	N	CIN2+	Immediate CIN2+ risk	SE	95% LCL	95% UCL
	HPV	Cytology							
			ALL	6554	112	5.48	0.66	4.19	6.78
		ASC-US	30–44	2091	280	14.77	0.73	13.33	16.21
			45–64	3039	356	12.19	0.58	11.05	13.32
			ALL	5130	636	13.24	0.52	12.22	14.25
		LSIL	30–44	843	119	14.63	1.04	12.59	16.67
			45–64	1019	96	12.07	0.88	10.35	13.79
			ALL	1862	215	13.23	0.87	11.52	14.94
		ASC-H	30–44	108	44	48.79	3.34	42.24	55.34
			45–64	185	77	43.28	3.18	37.05	49.52
			ALL	293	121	45.33	3.15	39.17	51.50
		AGC	30–44	60	24	55.02	4.22	46.74	63.29
			45–64	115	56	49.48	4.15	41.34	57.62
			ALL	175	80	51.35	4.11	43.30	59.41
		HSIL+	30–44	307	232	83.71	1.53	80.71	86.71
			45–64	360	272	80.45	1.72	77.09	83.82
			ALL	667	504	81.95	1.56	78.90	85.01
	Negative	NILM	30–44	27,401	8				
			45–64	59,786	11				
			ALL	87,187	19				
		ASC-US	30–44	3099	11				
			45–64	6827	20				
			ALL	9926	31				
		LSIL	30–44	280	9	3.57	1.10	1.42	5.73
			45–64	421	5	3.54	1.03	1.52	5.57
			ALL	701	14	3.58	0.99	1.64	5.51
		ASC-H	30–44	32	4	11.75	3.40	5.09	18.42
			45–64	128	12	11.66	2.77	6.24	17.09
			ALL	160	16	11.68	2.74	6.30	17.06
		AGC	30–44	78	4	9.51	2.24	5.11	13.90
			45–64	308	27	9.43	1.67	6.16	12.71
			ALL	386	31	9.45	1.62	6.29	12.62
		HSIL+	30–44	29	18	61.97	6.58	49.07	74.86
			45–64	56	30	61.77	5.90	50.20	73.34
			ALL	85	48	61.84	5.57	50.92	72.76

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 3

Immediate CIN2+ risk after the first screening with HPV by age, CDC's NBCCEDP (continued)

Population	Test results		Age category	N	CIN2+	Immediate CIN2+ risk	SE	95% LCL	95% UCL	
	HPV	Cytology								
Unknown screening history	Positive	NILM	30–44	1128	27	7.25	1.16	4.98	9.52	
			45–64	1437	15	5.59	0.92	3.79	7.40	
			ALL	2565	42	6.37	0.99	4.43	8.31	
		ASC-US	30–44	1087	162	16.07	1.08	13.95	18.18	
			45–64	1003	114	12.67	0.99	10.72	14.62	
			ALL	2090	276	14.49	0.85	12.83	16.15	
		LSIL	30–44	433	59	16.77	1.66	13.52	20.02	
			45–64	405	50	13.25	1.42	10.47	16.03	
			ALL	838	109	15.05	1.41	12.29	17.80	
	ASC-H	30–44	75	25	42.54	5.18	32.38	52.69		
		45–64	48	15	35.94	4.96	26.22	45.66		
		ALL	123	40	39.65	4.96	29.94	49.36		
	AGC	30–44	39	15	45.59	6.30	33.25	57.94		
		45–64	37	13	38.84	6.07	26.95	50.73		
		ALL	76	28	42.42	6.08	30.49	54.34		
	HSIL+	30–44	128	92	82.61	2.54	77.63	87.59		
		45–64	123	91	78.26	2.97	72.45	84.08		
		ALL	251	183	80.43	2.65	75.24	85.62		
	Negative	NILM	30–44	12,054	0					
			45–64	20,015	2					
			ALL	32,069	2					
			ASC-US	30–44	1228	5				
				45–64	2042	4				
				ALL	3270	9				
			LSIL	30–44	127	4	6.83	2.51	1.91	11.74
				45–64	166	5	5.17	1.97	1.30	9.04
				ALL	293	9	5.92	1.91	2.17	9.67
		ASC-H	30–44	13	0	3.63	3.69	0.00	10.87	
			45–64	30	1	2.73	2.71	0.00	8.04	
			ALL	43	1	2.94	2.90	0.00	8.62	
AGC		30–44	34	1	8.61	3.73	1.30	15.93		
		45–64	83	6	6.56	2.55	1.57	11.54		
		ALL	117	7	7.14	2.60	2.04	12.24		
HSIL+		30–44	12	9	61.83	11.15	39.98	83.67		
		45–64	15	6	54.66	11.30	32.51	76.81		
		ALL	27	15	57.99	10.15	38.10	77.88		

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 3

Immediate CIN2+ risk after the first screening with HPV by age, CDC's NBCCEDP (continued)

Population	Test results		Age category	N	CIN2+	Immediate CIN2+ risk	SE	95% LCL	95% UCL	
	HPV	Cytology								
Never/rarely screened/unknown	Positive	NILM	30–4	3570	79	6.53	0.64	5.28	7.78	
			45–64	5549	75	5.22	0.52	4.20	6.23	
			ALL	9119	154	5.80	0.55	4.73	6.88	
		ASC-US	30–44	3178	442	15.17	0.61	13.98	16.35	
			45–64	4042	470	12.35	0.50	11.37	13.32	
			ALL	7220	912	13.60	0.44	12.73	14.46	
		LSIL	30–44	1276	178	15.28	0.88	13.55	17.01	
			45–64	1424	146	12.44	0.75	10.97	13.90	
			ALL	2700	324	13.77	0.74	12.31	15.22	
	ASC-H	30–44	183	69	47.12	2.81	41.61	52.62		
		45–64	233	92	41.24	2.69	35.97	46.50		
		ALL	416	161	43.74	2.66	38.52	48.95		
	AGC	30–44	99	39	52.19	3.52	45.29	59.08		
		45–64	152	69	46.23	3.45	39.47	52.99		
		ALL	251	108	48.60	3.42	41.90	55.30		
	HSIL+	30–44	435	324	83.43	1.31	80.87	86.00		
		45–64	483	363	79.86	1.49	76.95	82.78		
		ALL	918	687	81.54	1.34	78.91	84.18		
	Negative	NILM	30–44	39,455	8					
				45–64	79,801	13				
				ALL	119,256	21				
			ASC-US	30–44	4327	16				
				45–64	8869	24				
				ALL	13,196	40				
			LSIL	30–44	407	13	4.43	1.04	2.39	6.48
				45–64	587	10	4.17	0.94	2.33	6.02
				ALL	994	23	4.29	0.90	2.53	6.05
		ASC-H	30–44	45	4	10.41	2.82	4.89	15.93	
			45–64	158	13	9.84	2.29	5.35	14.33	
			ALL	203	17	9.94	2.29	5.46	14.43	
AGC		30–44	112	5	9.32	1.91	5.57	13.07		
		45–64	391	33	8.80	1.42	6.02	11.58		
		ALL	503	38	8.92	1.38	6.21	11.63		
HSIL+		30–44	41	27	61.85	5.65	50.78	72.92		
		45–64	71	36	60.35	5.23	50.10	70.59		
		ALL	112	63	60.91	4.89	51.33	70.49		

AGC, atypical glandular cell; ASC-H, atypical squamous cells-cannot exclude; ASC-US, atypical squamous cells of uncertain significance; CDC, Centers for Disease Control and Prevention; CIN2, cervical intraepithelial neoplasia grade II; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LCL, lower confidence limits; LSIL, low-grade squamous intraepithelial lesion; NBCCEDP, National Breast and Cervical Cancer Early Detection Program; NILM, negative for intraepithelial lesion or malignancy; SE, standard error; UCL, upper confidence limits.

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. *Am J Obstet Gynecol* 2020.

SUPPLEMENTAL TABLE 4

Immediate cancer risk after the first screening with HPV by age, CDC's NBCCEDP

Population	Test results		Age category	N	Cancer	Immediate cancer risk	SE	95% LCL	95% UCL
	HPV	Cytology							
Screened in the past 5 y	Positive	NILM	30–44	4475	5	0.14	0.06	0.03	0.26
			45–64	6840	2	0.23	0.09	0.06	0.41
			All	11,315	7	0.2	0.07	0.05	0.34
		ASC-US	30–44	5107	6	0.14	0.04	0.07	0.22
			45–64	6647	16	0.23	0.05	0.12	0.34
			All	11,754	22	0.19	0.04	0.11	0.28
		LSIL	30–44	1822	1	0.14	0.06	0.02	0.26
			45–64	1906	5	0.23	0.1	0.04	0.42
			All	3728	6	0.19	0.08	0.04	0.34
	ASC-H	30–44	257	3	1.29	0.47	0.37	2.21	
		45–64	310	7	2.08	0.7	0.71	3.46	
		All	567	10	1.73	0.57	0.61	2.85	
	AGC	30–44	109	8	4.77	1.42	1.98	7.56	
		45–64	135	7	7.53	1.99	3.63	11.44	
		All	244	15	6.33	1.64	3.12	9.54	
	HSIL+	30–44	403	12	4.39	0.88	2.65	6.12	
		45–64	344	25	6.95	1.26	4.48	9.41	
		All	747	37	5.56	0.89	3.82	7.31	
	Negative	NILM	30–44	53,342	1				
			45–64	99,264	3				
			All	152,606	4				
		ASC-US	30–44	8216	1				
			45–64	16,970	6				
			All	25,186	7				
		LSIL	30–44	572	0				
			45–64	889	0				
			All	1461	0				
ASC-H		30–44	110	0					
		45–64	183	0					
		All	293	0					
AGC		30–44	196	1	0.81	0.5	0	1.8	
		45–64	473	11	2.22	0.69	0.87	3.56	
		All	669	12	1.81	0.46	0.91	3.21	
HSIL+		30–44	35	1	2.02	1.53	0	5.01	
		45–64	51	2	5.4	3.1	0	11.47	
		All	86	3	3.49	3.25	0.73	9.86	

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 4

Immediate cancer risk after the first screening with HPV by age, CDC's NBCCEDP (continued)

Population	Test results		Age category	N	Cancer	Immediate cancer risk	SE	95% LCL	95% UCL
	HPV	Cytology							
Never/rarely screened	Positive	NILM	30–44	2442	4	0.39	0.13	0.13	0.66
			45–64	4112	7	0.94	0.29	0.38	1.51
			All	6554	11	0.7	0.23	0.25	1.14
		ASC-US	30–44	2091	3	0.38	0.09	0.2	0.56
			45–64	3039	27	0.91	0.17	0.58	1.25
			All	5130	30	0.69	0.13	0.45	0.94
		LSIL	30–44	843	0	0.04	0.04	0	0.11
			45–64	1019	1	0.09	0.09	0	0.27
			All	1862	1	0.07	0.07	0	0.2
	ASC-H	30–44	108	3	3.05	0.95	1.18	4.91	
		45–64	185	12	7.07	1.84	3.47	10.67	
		All	293	15	5.58	1.45	2.74	8.42	
	AGC	30–44	60	7	7.57	2.06	3.54	11.6	
		45–64	115	13	16.55	3.4	9.89	23.21	
		All	175	20	13.51	2.81	8.01	19.02	
	HSIL+	30–44	307	15	5.7	1.09	3.56	7.84	
		45–64	360	43	12.76	1.69	9.45	16.07	
		All	667	58	9.51	1.19	7.18	11.84	
	Negative	NILM	30–44	27,401	1				
			45–64	59,786	5				
			All	87,187	6				
		ASC-US	30–44	3099	0				
			45–64	6827	2				
			All	9926	2				
		LSIL	30–44	280	0				
			45–64	421	0				
			All	701	0				
ASC-H		30–44	32	0					
		45–64	128	2	1.75	2.27	0.21	6.19	
		All	160	2	1.46	1.89	0.18	5.17	
AGC		30–44	78	2	2.78	3.52	0.34	9.68	
		45–64	308	15	5.86	1.85	3.32	9.48	
		All	386	17	5.18	1.52	3.05	8.17	
HSIL+		30–44	29	0					
		45–64	56	9	18.37	6.97	8.76	32.02	
		All	85	9	11.84	4.82	5.56	21.29	

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. Am J Obstet Gynecol 2020.

(continued)

SUPPLEMENTAL TABLE 4

Immediate cancer risk after the first screening with HPV by age, CDC's NBCCEDP (continued)

Population	Test results		Age category	N	Cancer	Immediate cancer risk	SE	95% LCL	95% UCL
	HPV	Cytology							
Unknown screening history	Positive	NILM	30–44	1128	1	0.44	0.23	0	0.9
			45–64	1437	3	0.81	0.41	0.01	1.6
			All	2565	4	0.63	0.32	0.01	1.25
		ASC-US	30–44	1087	7	0.62	0.19	0.25	1
			45–64	1003	8	1.14	0.32	0.52	1.76
			All	2090	15	0.86	0.22	0.43	1.3
		LSIL	30–44	433	2	0.88	0.35	0.2	1.55
			45–64	405	7	1.6	0.58	0.46	2.75
			All	838	9	1.23	0.43	0.38	2.08
	ASC-H	30–44	75	2	2.26	1.35	0	4.9	
		45–64	48	1	4.08	2.34	0	8.68	
		All	123	3	3.06	1.74	0	6.47	
	AGC	30–44	39	4	7.91	3.16	1.72	14.1	
		45–64	37	3	13.65	4.92	4.01	23.28	
		All	76	7	10.61	3.79	3.18	18.03	
	HSIL+	30–44	128	6	7.14	1.88	3.45	10.83	
		45–64	123	16	12.39	2.7	7.11	17.68	
		All	251	22	9.78	1.98	5.9	13.66	
	Negative	NILM	30–44	12,054	0				
			45–64	20,015	1				
			All	32,069	1				
		ASC-US	30–44	1228	0				
			45–64	2042	2				
			All	3270	2				
LSIL		30–44	127	0					
		45–64	166	2	2.41	3.07	0.29	8.43	
		All	293	2	1.32	0.92	0	3.13	
ASC-H		30–44	13	0					
		45–64	30	0					
		All	43	0					
AGC		30–44	34	0					
		45–64	83	5	7.14	4.46	2.36	15.89	
		All	117	5	5.10	2.22	0.75	9.46	
HSIL+	30–44	12	0						
	45–64	15	1	7.14	4.46	2.36	15.89		
	All	27	1	4.17	4.08	0.75	9.46		

AGC, atypical glandular cell; ASC-H, atypical squamous cells-cannot exclude; ASC-US, atypical squamous cells of uncertain significance; CDC, Centers for Disease Control and Prevention; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; NBCCEDP, National Breast and Cervical Cancer Early Detection Program; NILM, negative for intraepithelial lesion or malignancy; SE, standard error; UCL, upper confidence limits.

Saraiya et al. Risk of cervical precancer or cancer among underinsured and uninsured women. *Am J Obstet Gynecol* 2020.